WEBULL
WebtradeDownload

Should Updated COVID Vaccine Approvals Require Action From Novavax Stock Investors?

Simply Wall St · 2d ago
  • Novavax has seen sharp swings in recent days as vaccine stocks reacted to reports of a suspected plague case in Russia, followed by updated COVID-19 vaccine approvals and attention on its upcoming earnings, where estimates point to improved EPS alongside lower projected revenue.
  • The brief rally tied to plague headlines, despite Novavax having no product for that disease, underlines how sentiment can disconnect from its real business drivers such as COVID-19 demand, malaria vaccine commercialization, and partner royalty streams.
  • We will look at how Novavax's investment narrative is being tested by infectious disease headlines that have little to do with its pipeline.
Spot opportunities beyond the Novavax headlines by scanning a hand picked 29 high quality undervalued stocks.

Novavax Investment Narrative Recap

To own Novavax, you need to believe its protein based vaccines and Matrix M adjuvant can support a viable respiratory and infectious disease franchise as COVID revenue normalizes and malaria adoption broadens. The key near term swing factor remains execution around updated COVID shots and partner driven volumes, rather than headline driven trading around unrelated outbreaks.

In the short term, the most important catalyst is the upcoming earnings print, with the focus on how an improved EPS path is being achieved alongside lower expected revenue. The biggest risk is liquidity pressure if royalty and milestone inflows from partners lag, since the business is still loss making and carries negative shareholders equity.

Among recent developments, the approvals for Novavax's updated COVID 19 vaccine in key markets matter far more than the brief plague linked spike and reversal. That regulatory progress ties directly to near term demand for Nuvaxovid, to how much production needs to be supported, and to the timing of any volume related payments from partners.

Those COVID authorizations also sit alongside the R21 Matrix M malaria rollout in multiple African countries, which gives Novavax a second commercial leg that is less tied to seasonal boosters. For you as an investor, the operational question is whether COVID, malaria, and Sanofi led combination programs together can offset revenue pressure and reduce reliance on one product cycle.

Novavax's current earnings of $422.8 million are expected by analysts to decline to $55.9 million by 2028, implying an earnings decrease of about $367 million. Consensus forecasts point to 2028 revenue of $348.5 million and an annual revenue decline rate of 31.4% over the next 3 years.

Discover why Novavax's fair value points to a 23% potential upside to its current price, which could close faster than many expect.

NasdaqGS:NVAX 1-Year Stock Price Chart
NasdaqGS:NVAX 1-Year Stock Price Chart

Exploring Other Perspectives

You can read the recent Novavax swing as a sentiment story, yet the lowest analysts are far more focused on long term revenue pressure. Before the news, they were pencilling in about $250.1 million of sales and only $47.5 million of earnings by 2029. That is a much harsher take than consensus, and it shows how sharply opinions can differ. Treat the plague headlines as a fresh reason to compare these contrasting forecasts and consider which version of the future you find more believable.

Explore 2 other Novavax fair value estimates, including one that suggests it could be worth just $13.78!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own research and judgment.

Looking For More Investment Ideas Beyond Novavax?

If the recent moves in Novavax have you reassessing your watchlist, it can help to widen the lens and compare other businesses with very different risk and return profiles. The Simply Wall St Screener lets you do that quickly by surfacing focused sets of stocks built around specific financial traits, so you can pressure test your thesis instead of reacting only to headlines.

  • For investors who prefer stability and lower drawdowns, start with a basket of companies that score well on resilience and financial risk using our 31 resilient stocks with low risk scores.
  • If you are hunting for income ideas, filter for businesses that pair higher yields with balance sheets that can support ongoing payouts by reviewing the 8 dividend fortresses.
  • When you want to go beyond widely followed tickers, uncover lesser known businesses with solid fundamentals through the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.